Market revenue in 2023 | USD 4,405.8 million |
Market revenue in 2030 | USD 7,025.1 million |
Growth rate | 6.9% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 66.07% in 2023. Horizon Databook has segmented the U.S. blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
In the U.S., blood cancer is the most prevalent form of cancer. According to recent statistics from the American Cancer Society, it was estimated that over 186,000 new cases of blood cancer were to be diagnosed in 2023 in the U.S. This staggering number highlighted the significant burden of these malignancies on the country’s healthcare system and the critical need for effective diagnostic tools & treatment modalities.
The high prevalence of blood cancer in the U.S. can be attributed to several factors, including an aging population, environmental exposures, and genetic predispositions. In addition, advancements in diagnostic techniques have led to early detection and improved reporting of these cancers.
Regardless of the underlying causes, the pervasiveness of blood cancer presents a formidable challenge for healthcare providers, researchers, and policymakers, necessitating a concerted effort to develop innovative strategies for prevention, early detection, & personalized treatment approaches.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account